KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBITDA (2019 - 2025)

Royalty Pharma (RPRX) has disclosed EBITDA for 7 consecutive years, with $388.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 7.43% to $388.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 20.66% year-over-year, with the annual reading at $1.6 billion for FY2025, 20.66% up from the prior year.
  • EBITDA hit $388.4 million in Q4 2025 for Royalty Pharma, down from $427.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $735.1 million in Q3 2024 to a low of -$482.7 million in Q4 2022.
  • Historically, EBITDA has averaged $269.7 million across 5 years, with a median of $259.2 million in 2023.
  • Biggest five-year swings in EBITDA: tumbled 414.6% in 2022 and later surged 824.08% in 2025.
  • Year by year, EBITDA stood at $153.4 million in 2021, then crashed by 414.6% to -$482.7 million in 2022, then surged by 226.98% to $612.9 million in 2023, then crashed by 41.02% to $361.5 million in 2024, then rose by 7.43% to $388.4 million in 2025.
  • Business Quant data shows EBITDA for RPRX at $388.4 million in Q4 2025, $427.2 million in Q3 2025, and $209.8 million in Q2 2025.